SM-07883

SM-07883 is an investigational **oral, brain-penetrant small-molecule** kinase inhibitor developed by **Samumed** and later associated with **Biosplice Therapeutics** for **Alzheimer's disease**. It is described publicly as a **novel, potent, and selective DYRK1A inhibitor**, with secondary activity against **GSK-3β**, aiming to reduce pathological tau phosphorylation and related downstream neurodegenerative processes. In preclinical Alzheimer's and tauopathy models, SM-07883 reduced tau hyperphosphorylation, tau oligomerization and aggregation, neuroinflammation, and amyloid plaque burden, with associated cognitive or behavioral benefit. A first-in-human **Phase 1 single-ascending-dose study in healthy volunteers** was registered in Australia in 2019, but later literature indicates development was discontinued in favor of more selective next-generation DYRK1A inhibitors.

Other names

DYRK1A inhibitor (brain penetrant)